Expression of HAT1 and HDAC1, 2, 3 in Diffuse Large B-Cell Lymphomas, Peripheral T-Cell Lymphomas, and NK/T-Cell Lymphomas
Soo Kee Min, Young Ho Koh, Yunwoong Park, Hyo Jung Kim, Jinwon Seo, Hye-Rim Park, Seong Jin Cho, In Sun Kim
Korean J Pathol. 2012;46(2):142-150.   Published online 2012 Apr 25     DOI:
Citations to this article as recorded by Crossref logo
Emerging role of histone deacetylase inhibitors in the treatment of diffuse large B-cell lymphoma
Mingyang Wang, Xiaosheng Fang, Xin Wang
Leukemia & Lymphoma.2020; 61(4): 763.     CrossRef

Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases

Lijun Du, Lei Zhang, Ling Li, Xin Li, Jiaqin Yan, Xinhua Wang, Xiaorui Fu, Zhenchang Sun, Xudong Zhang, Zhaoming Li, Jingjing Wu, Hui Yu, Yu Chang, Zhiyuan Zhou, Feifei Nan, Xiaolong Wu, Li Tian, Mingzhi Zhang
OncoTargets and Therapy.2020; Volume 13: 7189.     CrossRef
Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer
Ping Fan, Jingyuan Zhao, Zibo Meng, Heyu Wu, Bo Wang, Heshui Wu, Xin Jin
Journal of Experimental & Clinical Cancer Research.2019;[Epub]     CrossRef
Histone modifications: A review about the presence of this epigenetic phenomenon in carcinogenesis
Emanuely Silva Chrun, Filipe Modolo, Filipe Ivan Daniel
Pathology - Research and Practice.2017; 213(11): 1329.     CrossRef
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Yixuan Li, Edward Seto
Cold Spring Harbor Perspectives in Medicine.2016; 6(10): a026831.     CrossRef
Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies
Diana Markozashvili, Vincent Ribrag, Yegor S. Vassetzky
Investigational New Drugs.2015; 33(6): 1280.     CrossRef
Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
Hervé Ghesquieres, Susan L. Slager, Fabrice Jardin, Amelie S. Veron, Yan W. Asmann, Matthew J. Maurer, Thierry Fest, Thomas M. Habermann, Marie C. Bene, Anne J. Novak, Sylvain Mareschal, Corinne Haioun, Thierry Lamy, Stephen M. Ansell, Herve Tilly, Thomas
Journal of Clinical Oncology.2015; 33(33): 3930.     CrossRef
Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis
Tobias Wagner, Peter Brand, Thorsten Heinzel, Oliver H. Krämer
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2014; 1846(2): 524.     CrossRef
Targetome profiling and functional genetics implicate miR-618 in lymphomagenesis
Alan Fu, Aaron E Hoffman, Ran Liu, Daniel I Jacobs, Tongzhang Zheng, Yong Zhu
Epigenetics.2014; 9(5): 730.     CrossRef
Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
Jinwon Seo, Soo Kee Min, Hye-Rim Park, Dong Hoon Kim, Mi Jung Kwon, Lee Su Kim, Young-Su Ju
Journal of Breast Cancer.2014; 17(4): 323.     CrossRef
Diffuse large B-cell lymphoma
Maurizio Martelli, Andrés J.M. Ferreri, Claudio Agostinelli, Alice Di Rocco, Michael Pfreundschuh, Stefano A. Pileri
Critical Reviews in Oncology/Hematology.2013; 87(2): 146.     CrossRef
Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma
Kelly A. Cycon, Kathleen Mulvaney, Lisa M. Rimsza, Daniel Persky, Shawn P. Murphy
Immunology.2013; 140(2): 259.     CrossRef